Loading... Please wait...
Sort by:

 

FirstView NPS+

An expanded view of brand loyalty among doctors

Actionable metrics to help you make better brand decisions

 

Net Promoter Score (NPS) is an easy way to measure brand health, but it doesn’t tell you how to improve it. NPS+ turns your Net Promoter Score into actionable information by answering key questions about brand loyalty

 

Each NPS+ report examines doctors’ relationships with the brands used to treat a major disease area—measuring brand loyalty and showing you how it affects your market share. NPS+ also examines “brand DNA”, revealing in doctors’ own words what brands mean to them.

 

Instead of one simple metric, NPS+ gives you a detailed picture of brand health that highlights areas for improvement, and helps you see exactly what steps you need to take next.

  • Pages:
  • 1
  • 2
  • NPS+ Multiple Myeloma (EU5) 2016
    Learn More NPS+ Multiple Myeloma (EU5) 2016
    Two brands are way out front in an otherwise unsatisfied market. Where does your brand rank? According to our survey of 150 medical oncologists and haematologists, doctors in the EU5 countries are not happy with available...
  • NPS+ Multiple Myeloma (US) 2016
    Learn More NPS+ Multiple Myeloma (US) 2016
    Overall satisfaction is high, but three brands are way ahead. Can your brand catch up? Our survey of 100 medical oncologists and haematologists shows that while US doctors are happy with available myeloma therapies, some...
  • NPS+ Multiple Sclerosis (EU5) 2016
    Learn More NPS+ Multiple Sclerosis (EU5) 2016
    One brand comes out ahead as low satisfaction scores plague MS therapies. Is your brand far behind? Multiple Sclerosis (MS) therapies have a big perception problem in the EU5 countries. Nearly half of the doctors we...
  • NPS+ Multiple Sclerosis (US) 2016
    Learn More NPS+ Multiple Sclerosis (US) 2016
    One brand comes out ahead as low satisfaction scores plague MS therapies. Is your brand far behind? Multiple Sclerosis (MS) therapies have a big perception problem. Over a third of the doctors we surveyed are unhappy with...
  • NPS+ Type 2 Diabetes Mellitus (EU) 2016
    Learn More NPS+ Type 2 Diabetes Mellitus (EU) 2016
    Which brands are edging ahead of the rest in the brand satisfaction stakes?  The EU market for Type 2 Diabetes Mellitus (T2DM) drugs has plenty of contenders – but which brands are the healthiest? What are the...
  • NPS+ Type 2 Diabetes Mellitus (US) 2016
    Learn More NPS+ Type 2 Diabetes Mellitus (US) 2016
    Which brands are edging ahead of the rest in the brand satisfaction stakes?  The US market for Type 2 Diabetes Mellitus (T2DM) drugs has plenty of contenders – but which brands are the healthiest? What are the...
  • NPS+ Rheumatoid Arthritis (EU5)
    Learn More NPS+ Rheumatoid Arthritis (EU5)
    Two leading brands continue to dominate satisfaction scores. Where does your brand rank? Few brands are earning high satisfaction scores in the European rheumatoid arthritis (RA) treatment market, but two long-time leaders...
  • NPS+ Rheumatoid Arthritis (US)
    Learn More NPS+ Rheumatoid Arthritis (US)
    Satisfaction survey results: Top 2 brands are way ahead of the pack. Can your brand close the gap? In the US rheumatoid arthritis (RA) treatment market, the two leading brands are trouncing the competition, earning far and...
  • NPS+ Growth Hormone Deficiency (EU5)
    Learn More NPS+ Growth Hormone Deficiency (EU5)
    Just one brand shows a positive Net Promoter Score in the EU: fertile ground for other brands to gain share? EU endocrinologists are not overly satisfied with current growth hormone deficiency treatment options, with only...
  • NPS+ Growth Hormone Deficiency (US)
    Learn More NPS+ Growth Hormone Deficiency (US)
    Could differentiation efforts boost some GHD brands in the US? Opportunity lurks in the US Growth hormone Deficiency treatment landscape. Although 3 established brands dominate, promoters of these brands are starting to...
  • NPS+ Non-Small Cell Lung Cancer (NSCLC) (US)
    Learn More NPS+ Non-Small Cell Lung Cancer (NSCLC) (US)
    In our satisfaction survey, one drug leaves the rest in the dust. How does your brand compare? We interviewed 100 US oncologists to find out how satisfied they are with non-small cell lung cancer (NSCLC) drugs. Which brand...
  • NPS+ Non-Small Cell Lung Cancer (NSCLC) (EU5)
    Learn More NPS+ Non-Small Cell Lung Cancer (NSCLC) (EU5)
    The race for 2nd place is on as one drug takes an impressive lead. Where does your brand rank? We interviewed 150 European oncologists to find out how satisfied they are with non-small cell lung cancer (NSCLC) drugs...
  • NPS+ Melanoma (EU5)
    Learn More NPS+ Melanoma (EU5)
    One brand is gaining ground in Europe – but who is coming a close second? When making melanoma treatment choices, are EU oncologists favouring particular brands? Oncologists claim to be broadly satisfied with the...
  • NPS+ Melanoma (US)
    Learn More NPS+ Melanoma (US)
    One brand leads the pack in the US – but who is coming a close second? When it comes to melanoma treatment options, just how loyal are US oncologists to particular brands? The majority claim to be satisfied with the...
  • NPS+ Psoriasis (EU5)
    Learn More NPS+ Psoriasis (EU5)
    Psoriasis: NPS results for psoriasis treatments show clear winners and losers. How does your brand rank? Physicians in the psoriasis market are showing decidedly low levels of loyalty, but high levels of satisfaction among...
  • NPS+ Psoriasis (US)
    Learn More NPS+ Psoriasis (US)
    Psoriasis: Low loyalty levels & high competition, how does your brand stack up? Physicians in the psoriasis market are showing decidedly low levels of loyalty, but high levels of satisfaction among the available brands...
  • Market Access Impact: HIV (US)
    Learn More Market Access Impact: HIV (US)
    Can prescription barriers help other HIV brands catch up to the runaway market leader? In the US HIV treatment market, the #1 brand has a 10% market share lead over its nearest rival. Will market barriers be the deciding...
  • Market Access Impact: HIV (EU5)
    Learn More Market Access Impact: HIV (EU5)
    Can prescription barriers help the 2nd and 3rd place HIV brands catch up to the runaway market leader? In the European HIV treatment market, the leading brand is comfortably ahead—but can market barriers help either...
  • NPS+ HIV (EU5)
    Learn More NPS+ HIV (EU5)
    Monotherapies trailing fixed-dose combinations for HIV. Where does your brand rank? Which HIV treatment gets the best satisfaction scores from Infectious Disease specialists? In Europe it isn't even close. Find which brand...
  • NPS+ HIV (US)
    Learn More NPS+ HIV (US)
    3 brands lead the HIV treatment market. How does your brand stack up? Satisfaction is running high for HIV treatments in the US Market. But Infectious Disease specialists show a clear preference for fixed-dose combinations...
  • Pages:
  • 1
  • 2

customer.service@firstwordpharma.com

All Contents Copyright © 2017 Doctor's Guide Publishing Limited All Rights Reserved